This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Chiron Mum as 2001 Passes Without Blood Test Approval

It may qualify as the least surprising biotech news of the new year, but Chiron (CHIR) failed to get its NAT blood-testing system approved by U.S. drug regulators by Dec. 31.

The Emeryville, Calif.-based biopharmaceutical firm had told investors and Wall Street analysts to expect Food and Drug Administration approval of the NAT blood test by the end of 2001. cast significant doubt on that prediction in late November, when a top U.S. blood-banking official said the heft of the approval application would keep the FDA busy until the middle of 2002.

In December, two Wall Street analysts joined the ranks of those believing NAT was delayed, lowering 2002 earnings estimates for Chiron as a result.

Despite missing its self-imposed deadline for NAT approval, Chiron has yet to issue a statement as to what went wrong or to say whether it has a new timetable for approval. Chiron executives would not return calls seeking comment.

The NAT blood-testing system, also known by the brand name Procleix, is designed to detect the presence of antigens such as HIV and hepatitis C in donated blood much earlier than current tests. NAT is Chiron's biggest potential growth driver, especially after the failure in November of its experimental sepsis drug. So, a long delay in the blood test's approval could force Chiron to reduce revenue and earnings estimates for the year.

Wall Street's view of Chiron's 2002 earnings outlook is already weakening, with consensus estimates dropping a penny to $1.15 per share, according to Thomson Financial/First Call.

Chiron closed out 2001 at $43.84 per share, a 1.5% drop for the year. Chiron shares closed Friday at $44.72.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs